EUCTR2011-001858-28-GB进行中（未招募）1 期
Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator's choice Modified MAGIC or FLOT regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction. - Neo-AEGIS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 540
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Countries with Group Specific Appendices with sections relating to the inclusion and exclusion criteria, should refer to this documents when reviewing patient eligibility.
- •1. Histologically verified adenocarcinoma of the oesophagus or oesophago-gastric junction based on endoscopy(OGD).
- •2. CT-18FDG-PET performed in all patients for disease staging
- •3. EUS in all patients unless luminal obstruction precludes sensitivity of the test.
- •4. Staging laparoscopy will be performed at the investigators discretion for locally advanced AEG II and AEG III tumours
- •5. Pre-treatment stage cT2-3, N0-3, M0
- •6. Maximum tumour length should be no more than 8cm (equal to 8 cm is acceptable).
- •7. Male/female patients aged =18 years.
- •8. ECOG Performance Status 0, 1 or 2 (Appendix F)
- •9. ASA Grading I-II (Appendix F).
- •10. Adequate cardiac function. For all patients an ejection fraction of > 50% is required. If patients have a known cardiac history (e.g. known ischemic disease, cardiomyopathy) an ejection fraction > 50% and cardiac clearance by a consultant cardiologist for major surgery and cancer therapies is required
- •11. Adequate respiratory function. Patients should have pulmonary function tests completed with a minimum FEV1 =1.5L. CPEX acceptable.
- •12. Adequate bone marrow function: absolute neutrophil count (ANC) >1.5x109/l; white blood cell count >3x109/l; platelets >100x109/l; haemoglobin (Hb) >9g/dl (can be post-transfusion).
- •13. Adequate renal function: glomerular filtration rate >60ml/minute calculated using the Cockcroft-Gault Formula(Appendix O).
- •14. Adequate liver function: serum bilirubin = ULN; AST <2.5x ULN and ALP <3x ULN (ULN as per institutional standard)
- •15. Written informed consent must be obtained from the patient before any study-specific procedures are performed.
- •16. Women of child-bearing potential and male subjects must agree to use an effective barrier method of contraception for up to 6 months following discontinuation of therapy. Effective contraception is defined as any medically recommended (or combination of methods) as per standard of care.
- •17. Women of childbearing potential must have pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to registration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 540
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 540
排除标准
- •Countries with Group Specific Appendices with sections relating to the inclusion and exclusion criteria, should refer to this documents when reviewing patient eligibility.
- •1. Tumours of squamous histology.
- •2. Patients with advanced inoperable or metastatic oesophageal, junctional or gastric adenocarcinoma.
- •3. Disease length (total length of tumour plus node) greater than 10 cm (up to 10 cm will be allowed) -measured by any modality or, if appropriate, combination of modalities-, unless in the opinion of the investigator in discussion with
- •national RT lead, it is felt that OAR constraints are likely to be achievable.
- •4. Any prior chemotherapy for gastrointestinal cancer.
- •5. Prior abdominal, thoracic, chest wall or breast radiotherapy.
- •6. Patients who are unfit for surgery or cancer treatments based on cardiac disease.
- •7. Patients with acute systemic infections.
- •8. Patients who are receiving treatment with sorivudine or its chemical related analogues, such as brivudine which is contraindicated with capecitabine and 5-fluorouracil administration.
- •9. Clinical COPD with significant obstructive airways disease classified by FEV1 < 1.5 L or PaO2 less than 9kPa on room air.
- •10. Known peripheral neuropathy >Grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible).
- •11. Known positive tests for human immunodeficiency virus (HIV) infection, acute or chronic active hepatitis B infection.
- •12. Any other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix).
- •13. Participation in other clinical trials of investigational or marketed agents for the treatment of oesophageal cancer or other diseases within 30 days prior to registration. UK sites please refer to Group Specific Appendix.
- •14. Women who are pregnant or breastfeeding.
- •15. Psychiatric illness/social situations that would limit compliance with study requirements.
- •16. Known Dihydropyrimidine dehydrogenase (DPD) deficiency
- •UK and French sites for inclusion and exclusion please refer to your country specific appendices.
研究者
相似试验
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 19.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ESIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-HUIRX Therapeutics, Inc.200
进行中（未招募）
1 期
A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavityewly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of theOral Cavity.MedDRA version: 20.0Level: PTClassification code 10041857Term: Squamous cell carcinoma of the oral cavitySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-000373-21-ITIRX THERAPEUTICS, INC.200
已完成
1 期
eo-adjuvant Progesterone and Vitamin D3 in Breast cancerCTRI/2013/06/003788Tata Memorial Hospital800
进行中（未招募）
1 期
eoadjuvant Lu-PSMA radioligand therapy and Ipilimumab in men with very high-risk prostate cancer (NEPI)Patients with very high-risk prostate cancer (as defined by a total Gleason-Score =4+4 [ISUP-GG 4+5] and clinical stage cT3 (digital rectal examinations or imaging based) plus clinical nodal status cN+ or Serum-PSA level > 20 ng/ml who are candidates for radical prostatectomy with pelvic lymph node dissection.CTIS2024-514386-19-00niversitaetsklinikum Essen AöR58